Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences By: Mirum Pharmaceuticals, Inc. via Business Wire May 18, 2022 at 18:30 PM EDT Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in the following upcoming virtual investor conferences: H.C. Wainwright Global Investment Conference Fireside chat on May 24, 2022 starting at 8:30 a.m. ET Jefferies Healthcare Conference Presentation on June 9, 2022 from 9:00-9:30 a.m. ET Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. LIVMARLI, an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 clinical trial for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC. Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for LIVMARLI for the treatment of cholestatic liver disease in patients with Alagille syndrome. Mirum’s second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis of pregnancy, and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis. Follow Mirum on Twitter, Facebook, LinkedIn and Instagram. View source version on businesswire.com: https://www.businesswire.com/news/home/20220518006159/en/Contacts Mirum Contacts: Media: Erin Murphy media@mirumpharma.com Investors: Ian Clements, Ph.D. ir@mirumpharma.com Sam Martin Argot Partners ir@mirumpharma.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences By: Mirum Pharmaceuticals, Inc. via Business Wire May 18, 2022 at 18:30 PM EDT Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in the following upcoming virtual investor conferences: H.C. Wainwright Global Investment Conference Fireside chat on May 24, 2022 starting at 8:30 a.m. ET Jefferies Healthcare Conference Presentation on June 9, 2022 from 9:00-9:30 a.m. ET Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. LIVMARLI, an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 clinical trial for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC. Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for LIVMARLI for the treatment of cholestatic liver disease in patients with Alagille syndrome. Mirum’s second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis of pregnancy, and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis. Follow Mirum on Twitter, Facebook, LinkedIn and Instagram. View source version on businesswire.com: https://www.businesswire.com/news/home/20220518006159/en/Contacts Mirum Contacts: Media: Erin Murphy media@mirumpharma.com Investors: Ian Clements, Ph.D. ir@mirumpharma.com Sam Martin Argot Partners ir@mirumpharma.com
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in the following upcoming virtual investor conferences: H.C. Wainwright Global Investment Conference Fireside chat on May 24, 2022 starting at 8:30 a.m. ET Jefferies Healthcare Conference Presentation on June 9, 2022 from 9:00-9:30 a.m. ET Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information. About Mirum Pharmaceuticals, Inc. Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum’s approved medication is LIVMARLI® (maralixibat) oral solution which is approved in the U.S. for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older. Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. LIVMARLI, an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 clinical trial for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b clinical trial for patients with biliary atresia. In addition, Mirum has an expanded access program open across multiple countries for eligible patients with ALGS and PFIC. Mirum has submitted a Marketing Authorization Application to the European Medicines Agency for LIVMARLI for the treatment of cholestatic liver disease in patients with Alagille syndrome. Mirum’s second investigational treatment, volixibat, an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the VISTAS Phase 2b clinical trial for adults with primary sclerosing cholangitis, the OHANA Phase 2b clinical trial for pregnant women with intrahepatic cholestasis of pregnancy, and the VANTAGE Phase 2b clinical trial for adults with primary biliary cholangitis. Follow Mirum on Twitter, Facebook, LinkedIn and Instagram. View source version on businesswire.com: https://www.businesswire.com/news/home/20220518006159/en/
Mirum Contacts: Media: Erin Murphy media@mirumpharma.com Investors: Ian Clements, Ph.D. ir@mirumpharma.com Sam Martin Argot Partners ir@mirumpharma.com
